Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy

In lung cancer, several potential mechanisms of intrinsic and acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been explored, including mesenchymal-epithelial transition factor (MET) signaling pathway activation. On the other hand, vascular endoth...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Case Rep Oncol
Päätekijät: Seki, Nobuhiko, Natsume, Maika, Ochiai, Ryosuke, Haruyama, Terunobu, Ishihara, Masashi, Fukasawa, Yoko, Sakamoto, Takahiko, Tanzawa, Shigeru, Usui, Ryo, Honda, Takeshi, Ota, Shuji, Ichikawa, Yasuko, Watanabe, Kiyotaka
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: S. Karger AG 2019
Aiheet:
Case Report
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6381877/
https://ncbi.nlm.nih.gov/pubmed/30792648
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000493088
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia